Business Context and Reporting Period
This Form 6-K filing by CollPlant Holdings Ltd. (CollPlant Biotechnologies Ltd) covers the month of February 2019. The report primarily addresses a significant change in corporate governance: the appointment of Jonathan M.N. Rigby as the new Chairman of the Board, effective January 30, 2019, replacing David Tsur.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and compensation agreements rather than financial performance.
Material Changes
- Leadership Transition: Jonathan M.N. Rigby was appointed Chairman of the Board, effective January 30, 2019. David Tsur stepped down as Chairman and Board member.
- Compensation Agreement: A Chairman Services Agreement was entered into on February 3, 2019, subject to shareholder approval.
- Compensation Terms: Mr. Rigby is entitled to an annual fee of $70,000 plus VAT, paid monthly.
- Equity Grant: Mr. Rigby received options to purchase 12,319,500 ordinary shares (246,390 ADSs) at an exercise price of $5.07 per share.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors beyond the standard terms of the executive agreement. Key terms of the agreement include:
- Vesting Schedule: Options vest upon the earlier of an equity raise of at least $10 million or a four-year schedule (25% on January 31, 2020, with the remainder vesting quarterly).
- Termination: The engagement is terminable by either party with 30 days' prior written notice, except in cases of termination for cause.
- Restrictions: The agreement includes a six-month non-compete obligation following termination.
Investor Verification Checklist
- Verify shareholder approval status for the Chairman Services Agreement and the associated equity grant.
- Confirm the current status of the $10 million equity raise required for accelerated option vesting.
- Review the impact of the leadership change on the company's strategic direction, given Mr. Rigby's background in specialty pharmaceuticals (SteadyMed, Zogenix, Xeris).
- Check subsequent filings for any financial updates, as this 6-K contains no financial data.